Inactive Instrument

News Briacell Therapeutics Corp Toronto S.E.

Equities

CA10778Y1043

Summary

Unlock all the news: Be the first to know and act before the market!

BriaCell Therapeutics : NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS Form 8 K	06-14	PU
BriaCell Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024	06-14	CI
BriaCell Presents Clinical Efficacy Data at ASCO 2024	06-03	AQ
Briacell Therapeutics Corp. Presents Clinical Efficacy Data At ASCO 2024	06-03	CI
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS in Advanced Metastatic Breast Cancer	05-31	AQ
BriaCell Begins Patient Enrollment in First-in-Human Study of Bria-OTS in Advanced Metastatic Breast Cancer	05-30	MT
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer	05-30	AQ
BriaCell Therapeutics Corp. Initiates Patient Enrollment in First-In-Human Study of Bria-Ots in Advanced Metastatic Breast Cancer	05-30	CI
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study	05-28	MT
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments	05-28	MT
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study	05-28	AQ
BriaCell Therapeutics Corp. Announces Clinical Supply Agreement with BeiGene, Ltd. for Bria-OTS First in Human Study	05-28	CI
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024	05-24	AQ
Briacell Therapeutics Insider Bought Shares Worth $2,000,001, According to a Recent SEC Filing	05-20	MT
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering	05-17	AQ
BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble	05-15	MT
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering	05-15	AQ
BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting	04-24	MT
BriaCell Announces Oral and Poster Presentations at ASCO 2024	04-24	AQ
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer	04-10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Briacell Therapeutics Corp Toronto S.E.

Equities

CA10778Y1043

Summary

Filters